Allergan faced intense criticism over its attempt to protect Restasis patents through sovereign immunity, and now an appeals court has ruled the strategy won't fly. The U.S. Court of Appeals for the ...
When Allergan transferred six Restasis patents to the Saint Regis Mohawk tribe in 2017 in a bid to shield the dry-eye treatment from generic competition, it was widely maligned by everyone from ...
Why are Americans, both as patients and taxpayers, paying billions of dollars for a drug whose efficacy is so questionable that it's not approved in the European Union, Australia or New Zealand?
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback